See previous post here. Novopharm is the #2 Canadian generic by sales in 2007; ratiopharm was the #4.
Article in NY Times is here. Price: $5 billion.
The Five-Year IP Roadmap Is Over: How to Build an IP Strategy for a Future
You Can’t Predict
-
Long-lived patents, an AI-shifted landscape: why a fixed filing roadmap
fails, and the three decision rules an IP strategy needs instead.
5 days ago
No comments:
Post a Comment